2007
DOI: 10.1161/circulationaha.106.641407
|View full text |Cite
|
Sign up to set email alerts
|

FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice

Abstract: Background-Numerous in vitro studies suggest that sphingosine 1-phosphate (S1P), a bioactive lysosphingolipid associated with high-density lipoproteins, accounts at least partly for the potent antiinflammatory properties of high-density lipoprotein and, thereby, contributes to the antiatherogenic potential attributed to high-density lipoproteins. The present study was undertaken to investigate whether modulation of S1P signaling would affect atherosclerosis in a murine model of disease. Methods and Results-Low… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

9
178
2
1

Year Published

2007
2007
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 207 publications
(190 citation statements)
references
References 53 publications
9
178
2
1
Order By: Relevance
“…14,15 Moreover, FTY720 attenuates asthma, arthritis, and atherosclerosis in animal models. [53][54][55] Therefore, we hypothesize that the suppressive effects of FTY720 on asthma and atherosclerosis may partly be attributed to the inhibition of cytokine production by NKT cells. Taken together, these data indicate that FTY720 is a candidate NKT cell-based therapeutic agent for the regulation of immune diseases, such as rheumatoid arthritis, asthma, and atherosclerosis.…”
Section: Discussionmentioning
confidence: 99%
“…14,15 Moreover, FTY720 attenuates asthma, arthritis, and atherosclerosis in animal models. [53][54][55] Therefore, we hypothesize that the suppressive effects of FTY720 on asthma and atherosclerosis may partly be attributed to the inhibition of cytokine production by NKT cells. Taken together, these data indicate that FTY720 is a candidate NKT cell-based therapeutic agent for the regulation of immune diseases, such as rheumatoid arthritis, asthma, and atherosclerosis.…”
Section: Discussionmentioning
confidence: 99%
“…Studies reveal an involvement for S1P in asthma, RA, IBD and atherosclerosis (Ammit et al, 2001;Kitano et al, 2006;Daniel et al, 2007;Nofer et al, 2007). Attempts have been made to produce antagonists to the S1P receptors, for example FTY720, and it has been demonstrated to ameliorate disease pathogenesis in models of colitis and atherosclerosis (Daniel et al, 2007;Nofer et al, 2007).…”
Section: Future Drug Targetsmentioning
confidence: 99%
“…FTY720 is currently being used in phase III clinical trials for multiple sclerosis (6) and has been shown to prevent onset of autoimmune diabetes in mouse models in vivo (7). Nofer et al (8) have recently reported that FTY720 reduces atherosclerosis in LDL receptor-deficient mice. Other studies have shown the importance of S1P and the S1P1 receptor in modulating T-cell proliferation and homing to lymph nodes (9,10).…”
mentioning
confidence: 99%